ACDM News Item

Regulatory Considerations DMEG Update

Date: December 4, 2025

With mixed feelings, we share that Silvia Pérez Torres, current chair of the ACDM Regulatory Considerations DMEG, will step down after five years of dedicated service. As a founding member, Silvia helped launch the DMEG in February 2021. Silvia set a clear vision, built a high‑performing, inclusive team across the world, and cultivating a culture of collaboration and excellence across the group and the wider ACDM community.

Under Silvia’s leadership, the DMEG coordinated consensus feedback to regulators on key publications from ICH, EMA, and FDA, and translated evolving requirements—such as ICH E6(R3), ICH E8(R1), FDA Digital Health Technologies, Data Monitoring Committees, and the Q&A on Electronic Systems, Records, and Signatures—into practical guidance and best practices for data management. She also helped connect the community through initiatives like the Hot Topic session on ICH E6(R3) and the ACDM publication, “Getting Started with Audit Trail Review in Clinical Trial Data.”

Thank you, Silvia, for your leadership, team building, and collaborative spirit—your impact on our community is lasting.

Looking ahead, Linda Shostak, a current DMEG member, will assume the chair role in January 2026. Silvia and Linda will work closely to ensure a smooth transition and continued momentum into 2026. Please join us in thanking Silvia for her outstanding service and in welcoming Linda to her new leadership role.

If you are interested in learning more about the Regulatory considerations DMEG or are interested in joining the group you can locate us on the ACDM website here.

Explore More News

Guidance on Decentralized Clinical Trials to be Reviewed by the ACDM RC DMEG

Health Canada (HC) continues to publish new guidelines to support their modernization of . . .

Regulatory Considerations DMEG to Review Health Canada’s Draft Guidance

Thank you to the Regulatory Considerations DMEG for sharing this update. Health Canada . . .

Recent update from the regulatory landscape in clinical data management

Thank you to the Regulatory Considerations DMEG for sharing this update. On July 15 the . . .

Regulatory Considerations DMEG Update – June 2026

Please read the following update from the Regulatory Considerations DMEG: Regulators have . . .

FDA Announces New Initiative for Real-Time Clinical Trials

The U.S. Food and Drug Administration (FDA) has announced a new initiative to support the . . .

Get to know ACDM Board Member Jennifer Duff

We caught up with one of ACDM’s new Board Members, Jennifer Duff, to learn more about her. . . .

Recent News in Regulatory Landscape

The ACDM Regulatory Considerations DMEG have kindly put together a short news piece . . .

Real-Time Clinical Data Flow: Why the FDA’s New Pilot Validates the Data Flow Modernization Agenda

Tamer Chowdhury, on behalf of ACDM Technology DMEG. On April 28, FDA Commissioner Dr. . . .

Bridging the Behaviour Gap: The Human Skills Redefining Clinical Data Management (ACDM26 Workshop Recap)

This article has been written by Gail Kniveton, who delivered the workshop “Bridging the . . .

Regulatory Considerations DMEG reviews recent MHRA regulatory updates

The ACDM Regulatory considerations DMEG Regulatory considerations reviewed several recent . . .

ACDM26 Berlin: Shaping the Future of Clinical Data Management

The ACDM Annual Conference returned to Berlin in March 2026, welcoming the global clinical . . .

Member News Update from Lab Data Solutions LLC

This news piece has been submitted by Lab Data Solutions LLC We’re Attending US Summit . . .